X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stenoparib
Therapeutic Area: Infections and Infectious Diseases Product Name: 2X-121
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2020
Details:
Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment. With the amendment, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Sosei Heptares has successfully designed three distinct series of compounds. These compounds have demonstrated high potency in inhibiting the activity of the Mpro protease as well as promising oral bioavailability and blood plasma levels in animal studies.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
